New Agents in Melanoma: Nivolumab, MK-3475, Pidilizumab

June 26, 2014
Michael B. Atkins, MD
Michael B. Atkins, MD

Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where a new agent, pidilizumab, fits into the picture.

Michael B. Atkins, MD, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center, offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab) and insights as to which anti-PD1 agents are also showing the greatest promise in non-melanoma cancers. Dr. Atkins presented on phase II results of the new anti-PD1 drug pidilizumab at the 2014 ASCO Annual Meeting and weighs in on where this new agent fits into the picture.